Skip to content

Control of foot placement to counteract perturbations during walking

Control of foot placement to counteract perturbations during walking - Control of foot placement during walking

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35344
Enrollment
17
Registered
2011-10-18
Start date
2012-01-25
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

verminderde of beschadigde sensorisch en/of motorische systemen decreased or impaired sensory and/or motor systems

Interventions

In this study there is one intervention. The balance of the subjects will be disturbed during walking in a balance experiment. This is done bij translations of a motion platform

Sponsors

Universiteit Twente
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * age > 18 years * able to walk on a treadmill

Exclusion criteria

Exclusion criteria: Healthy subjects are excluded if they: * have current orthopaedic problems * have other neurological disorders * have a history of cardiac conditions that interfere with physical load * have chronic joint pain * are pregnant

Design outcomes

Primary

MeasureTime frame
Change in foot placement as a response to the perturbations. Foot placement can be determined by the exact position where the foot is placed with respect to the other foot. Because balance control in lateral direction is most important in human balance control the main study parameter will be the step width.

Secondary

MeasureTime frame
• Standard gait parameters like step width, step time, swing time and stance time • Path of the CoP during single stance • Deviation of the CoM position and velocity changes of the CoM as a result of the perturbations • Muscle activation of arm and leg muscles as a result of the perturbations

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)